8-K: Avalo Therapeutics Completes Phase 2 HS Enrollment

Avalo Therapeutics announces completion of enrollment for its Phase 2 LOTUS trial of AVTX-009 for Hidradenitis Suppurativa, with topline data expected Q2 2026.

Summary

• Avalo Therapeutics, Inc. (AVTX) has completed enrollment for its Phase 2 LOTUS trial (AVTX-009-HS-201, NCT06603077) evaluating AVTX-009 for Hidradenitis Suppurativa (HS).
• Topline data from the Phase 2 LOTUS trial is expected in Q2 2026.
• AVTX-009 is a high-affinity, IL-1 specific monoclonal antibody with potential for a best-in-class and best-in-disease profile in HS.
• The company projects a cash runway into 2028, supported by approximately $112 million in cash, cash equivalents, and short-term investments as of September 30, 2025.
• The HS market is expected to grow to over $10 billion by 2035, driven by increased diagnosis and treatment rates.
• AVTX-009 is designed to target IL-1, a key driver of inflammation in HS, and has shown potential profile advantages over lutikizumab, including 15x higher affinity and a longer half-life.

Sentiment

Score: 8

Explanation: The filing indicates strong positive momentum with the completion of Phase 2 enrollment for a key asset targeting a large, growing market with unmet needs. The differentiated profile of AVTX-009 and a solid cash runway into 2028 are significant positives, although the ultimate success hinges on future clinical data.

Positives

• Enrollment for the Phase 2 LOTUS trial in Hidradenitis Suppurativa (HS) is complete, a significant clinical milestone.
• Topline data from the Phase 2 trial is anticipated in Q2 2026, providing a clear near-term catalyst.
• AVTX-009 demonstrates a differentiated profile with 15x higher affinity and a longer half-life than lutikizumab, potentially leading to higher efficacy and less frequent dosing.
• The company has an expected cash runway into 2028, providing financial stability through key clinical readouts.
• The target market, Hidradenitis Suppurativa, is projected to grow substantially to over $10 billion by 2035, indicating significant commercial potential.
• AVTX-009 specifically targets IL-1, which is identified as a central driver in HS pathophysiology, suggesting a strong mechanistic rationale.

Risks

• Drug development costs and the timing of trial results are subject to significant risks and uncertainties.
• Reliance on investigators and enrollment of patients in clinical trials can impact timelines and outcomes.
• General economic and market risks and uncertainties, including those caused by geopolitical events like the war in Ukraine and the Middle East, could affect operations.
• Reliance on key personnel is a factor for the company's success.
• Regulatory risks are inherent in the pharmaceutical development process.
• Actual results may differ from forward-looking statements due to various factors beyond Avalo's control.

Future Outlook

Topline data from the Phase 2 LOTUS trial for AVTX-009 in Hidradenitis Suppurativa is expected in Q2 2026. Following a successful Phase 2 readout, the company plans to initiate a pivotal program in 2027. The Hidradenitis Suppurativa market is projected to grow significantly, exceeding $10 billion by 2035. The company anticipates its current cash reserves will fund operations into 2028.

Management Comments

• The Avalo management team has a proven track record of successful leadership, product development, and commercialization in pharma and biotech, with over 220 years of combined experience.
• The company's mission is advancing an inspired pipeline of novel IL-1 therapies focused on treating unmet medical needs.

Industry Context

The announcement positions Avalo Therapeutics within the competitive landscape of immune-mediated inflammatory diseases, specifically Hidradenitis Suppurativa (HS). Current treatments for HS, such as anti-TNF (e.g., Humira) and anti-IL-17 (e.g., Cosentyx, Bimzelx) biologics, often result in incomplete response or loss of response, highlighting a significant unmet need. Avalo's AVTX-009 targets IL-1, an upstream immunoregulator, which has shown clinical benefit in HS with other anti-IL-1 drugs like lutikizumab. The HS market is experiencing substantial growth, driven by increased diagnosis and treatment rates, making it an attractive area for novel therapies.

Comparison to Industry Standards

• AVTX-009 exhibits 15x higher affinity and a longer half-life compared to AbbVie's lutikizumab (IL-1α/β targeting mAb), potentially leading to superior efficacy and less frequent dosing in HS.
• Lutikizumab demonstrated favorable Phase 2 efficacy in a refractory HS population (71% Hurley stage III) that had failed anti-TNF therapy, suggesting the importance of IL-1 targeting.
• In contrast, bermekimab, an IL-1β specific mAb, performed no better than placebo in a Phase 2 study, indicating that IL-1β alone may not be the primary driver in HS, unlike AVTX-009's IL-1 specificity.
• The HS market is projected to grow to over $10 billion by 2035, with diagnosed and treated patients increasing from 30% to 45% of the total population, and biologics-treated patients increasing to ~40% share of the segment, comparable to the rapid adoption seen with Cosentyx and Bimzelx.

Stakeholder Impact

• Shareholders: The completion of Phase 2 enrollment and anticipated Q2 2026 data readout represent key value inflection points, potentially increasing shareholder value if results are positive. The extended cash runway provides financial stability.
• Patients (Hidradenitis Suppurativa): AVTX-009 offers a potential new treatment option for a debilitating disease with significant unmet needs, particularly for those refractory to current therapies.
• Employees: Continued clinical progress and financial stability provide job security and opportunities for growth within the company.
• Healthcare Providers: A successful AVTX-009 could provide a novel, potentially more effective, therapeutic tool for managing HS patients.

Next Steps

• Anticipate topline data readout from the Phase 2 LOTUS trial in Q2 2026.
• Initiate a pivotal program in 2027, pending the results of the Phase 2 study.
• Continue assessing additional immunology indications for investment to broaden the pipeline.

Key Dates

Recommendation

The completion of Phase 2 enrollment for AVTX-009 in Hidradenitis Suppurativa is a significant positive milestone, and the projected cash runway into 2028 provides stability. The drug's differentiated profile and the large, growing market for HS are attractive. However, as a pre-revenue biotech, the stock's valuation remains highly dependent on the upcoming Phase 2 topline data in Q2 2026. A 'hold' recommendation is prudent for a seasoned investor, allowing for observation of these critical results before making a more definitive investment decision, balancing the strong potential with the inherent risks of clinical development.

Keywords

Avalo Therapeutics, AVTX, Hidradenitis Suppurativa, HS, IL-1, AVTX-009, Clinical Trial, Phase 2, Biotechnology, Immunology, Inflammatory Diseases, Monoclonal Antibody